Abstract Introduction CPX-351 is a liposomal formulation that encapsulates cytarabine and daunorubicin at a 5:1 molar ratio. This molar ratio was found, in vitro, to be consistently synergistic and nonantagonistic across multiple leukemic and solid tumor cell lines. A randomized phase II study comparing CPX-351 with conventional cytarabine + daunorubicin (7 + regimen) in patients with acute myeloid leukemia (AML) aged 60-75 years is currently in follow-up. This report presents interim safety and efficacy data for 85 of the 126 subjects treated on this study. Patients and Methods Eligible patients included those with de novo or secondary AML, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, SCr 50% by echo or multigated acquisition (MUGA). Exclusions were made for acute promyelocytic leukemia (t[15;17]), known favorable cytogenetics (eg, t[8;21] and inv[16]), > 368 mg/m 2 of prior anthracycline exposure, New York Heart Association (NYHA) class III/IV myocardial impairment, uncontrolled infections, prior treatment for AML (except for hydroxyurea), active central nervous system (CNS) leukemia, and conditions preventing ability to give informed consent. Results Data collected by 15 August 2009 for the first 85 patients enrolled were evaluated for interim safety and efficacy. Fifty-seven patients were randomized to CPX-351 and 28 patients to 7 + 3 control. The median age was 68 years; most patients were male (70.6%), had ECOG PS of 0 or 1 (83.5%), and had de novo AML (66%). The CPX-351 arm had more patients with ECOG PS of 2 (21.1% vs. 7.1%) and a higher proportion of patients with baseline white blood cell count (WBC) > 20,000/μL (22.9% vs. 14.3%). All 85 patients experienced at least 1 adverse event. Mortality at 30 days was low in both study arms (5.3% and 3.6%). Serious adverse events (SAEs) were more frequent in the CPX-351 arm and consisted predominantly of cytopenia-related events associated with treatment or leukemia, including fever and febrile neutropenia, sepsis, pneumonia, major bleeding episodes, and a number of minor infections. Although SAEs appeared to be more frequent following CPX-351, there was no evidence for this difference leading to an increase in deaths on study. Among other adverse events, CPX-351 appeared to have comparable rates of skin rash (57.9% vs. 57.1%) and gastrointestinal adverse events (nausea: 56.1% vs. 57.1%; vomiting: 17.5% vs. 28.6%; stomatitis: 21.1% vs. 21.4%; diarrhea: 61.4% vs. 64.3%). As noted in the phase I study, grade 3 gastrointestinal adverse events were uncommon. Peripheral blood count recovery was slower for the CPX-351 arm for both absolute neutrophil count (ANC) recovery to > 500/μL (37.5 days vs. 28 days) and platelet count recovery to > 20,000/μL (28 days vs. 21 days). CPX-351 treatment resulted in higher rates of CR + CRi (61.4% vs. 50%). This interim analysis has produced encouraging signs of antileukemic activity for CPX-351 consistent with earlier clinical findings. The study has completed enrollment and follow-up for CR duration and percent survival at 1 year will be completed by the end of 2010.